|
Percentage change from baseline in lipid variables at 4 weeks (ITT population) |
||||
| Variable |
Least-squares mean percentage change from baseline to 4 weeks |
Difference (95% CI) |
p-value |
|
|
|
||||
| Rosuvastatin 10 mg (n = 232) |
Atorvastatin 10 mg (n = 231) |
|||
|
|
||||
| LDL-C |
-47.6 |
-38.5a |
-9.1 (-11.4, -6.7) |
< 0.0001 |
| TC |
-33.6 |
-27.9 |
-5.7 (-7.4, -4.0) |
< 0.0001 |
| HDL-C |
4.4 |
2.6 |
1.8 (-0.5, 4.0) |
NS |
| TG |
-19.2 |
-15.5 |
-3.7 (-9.5, 2.2) |
NS |
| Non-HDL-C |
-42.6 |
-35.0 |
-7.6 (-9.6, -5.7) |
< 0.0001 |
| LDL-C/HDL-C ratio |
-49.3 |
-39.5 |
-9.8 (-12.2, -7.4) |
< 0.0001 |
| Non-HDL-C/HDL-C ratio |
-44.4 |
-35.9 |
-8.5 (-10.8, -6.2) |
< 0.0001 |
| TC/HDL-C ratio |
-35.8 |
-29.0 |
-6.7 (-8.7, -4.8) |
< 0.0001 |
| Apo B |
-42.9 |
-35.3 |
-7.6 (-9.7, -5.6) |
< 0.0001 |
| Apo A-I |
2.6 |
0.8 |
1.8 (0, 3.5) |
0.05 |
| Apo B/apo A-I ratio |
-43.9 |
-35.4 |
-8.5 (-10.6, -6.4) |
< 0.0001 |
|
ITT: Intention to treat, CI: Confidence interval, LDL-C: Low-density lipoprotein cholesterol, TC: Total cholesterol, HDL-C: High-density lipoprotein cholesterol, TG: Triglycerides, Apo: Apolipoprotein, NS: Not statistically significant an = 232 | ||||
Berne et al. Cardiovascular Diabetology 2005 4:7 doi:10.1186/1475-2840-4-7 |
||||